TD Cowen Issues Pessimistic Forecast for Surgery Partners (NASDAQ:SGRY) Stock Price

Surgery Partners (NASDAQ:SGRY) had its price objective lowered by TD Cowen from $28.00 to $20.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s price target points to a potential upside of 42.86% from the stock’s current price.

Other analysts have also recently issued research reports about the company. Royal Bank Of Canada reduced their price objective on Surgery Partners from $31.00 to $20.00 and set an “outperform” rating for the company in a research report on Wednesday. UBS Group reduced their price objective on Surgery Partners from $29.00 to $21.00 and set a “buy” rating for the company in a research report on Thursday. Barclays cut their price target on Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating for the company in a report on Tuesday. JPMorgan Chase & Co. reduced their price objective on shares of Surgery Partners from $27.00 to $20.00 and set a “neutral” rating for the company in a report on Monday, November 24th. Finally, Benchmark reiterated a “buy” rating on shares of Surgery Partners in a research note on Tuesday. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Surgery Partners has an average rating of “Moderate Buy” and an average price target of $24.45.

Surgery Partners Trading Down 0.6%

NASDAQ SGRY traded down $0.08 on Thursday, hitting $14.00. 911,582 shares of the company were exchanged, compared to its average volume of 1,697,499. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.87 and a quick ratio of 1.72. Surgery Partners has a twelve month low of $12.25 and a twelve month high of $24.64. The firm has a market capitalization of $1.81 billion, a P/E ratio of -22.58 and a beta of 1.95. The company’s 50 day moving average price is $15.28 and its 200-day moving average price is $18.24.

Surgery Partners (NASDAQ:SGRY) last released its earnings results on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.19). The firm had revenue of $885.00 million during the quarter, compared to analysts’ expectations of $866.54 million. Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.The business’s revenue was up 2.4% on a year-over-year basis. During the same period last year, the business earned $0.44 earnings per share. Analysts predict that Surgery Partners will post 0.67 earnings per share for the current fiscal year.

Surgery Partners announced that its Board of Directors has approved a stock repurchase plan on Thursday, February 26th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the company to reacquire up to 9.7% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On Surgery Partners

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pentwater Capital Management LP grew its position in shares of Surgery Partners by 66.9% during the 3rd quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company’s stock worth $252,777,000 after buying an additional 4,681,000 shares during the period. UBS Group AG boosted its stake in Surgery Partners by 111.4% during the 4th quarter. UBS Group AG now owns 7,803,974 shares of the company’s stock worth $120,571,000 after acquiring an additional 4,113,052 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Surgery Partners by 528.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,959,686 shares of the company’s stock valued at $30,277,000 after purchasing an additional 1,647,714 shares during the period. Glenview Capital Management LLC bought a new stake in Surgery Partners in the second quarter valued at approximately $33,995,000. Finally, King Street Capital Management L.P. raised its holdings in Surgery Partners by 24.5% in the second quarter. King Street Capital Management L.P. now owns 6,225,000 shares of the company’s stock worth $138,382,000 after purchasing an additional 1,225,000 shares during the period.

Surgery Partners News Summary

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Board authorizes $200M share repurchase (up to ~9.7% of shares), signaling management believes the stock is undervalued and providing buy-side support. RTT News: Buyback
• Positive Sentiment: Surgery Partners completed the acquisition of Preferred Vascular Group (8 ASCs focused on dialysis access), expanding its ASC footprint and specialized service mix. Strategic M&A can support growth and revenue diversification. PR Newswire: PVG Acquisition
• Positive Sentiment: UBS kept a “buy” rating despite cutting its price target from $29 to $21 — the new target still implies substantial upside from current levels, which may attract value-seeking investors. Benzinga: UBS PT Cut
• Neutral Sentiment: Mizuho trimmed its target from $19 to $17 and maintained an “outperform” rating, reducing upside but not turning bearish. Benzinga: Mizuho PT Cut
• Neutral Sentiment: Coverage and transcripts of the Q4 2025 earnings call highlight revenue growth but emphasize margin pressure and an EPS miss — mixed operational signals that leave valuation judgments split. Yahoo Finance: Q4 Highlights
• Negative Sentiment: Barclays lowered its price target to $14, close to current trading levels, reducing upside expectations from that broker and increasing near-term downside risk. American Banking News: Barclays PT Cut
• Negative Sentiment: Multiple outlets report SGRY hit a 52-week low after the earnings release; this technical weakness can prompt further selling and deter short-term buyers. MSN: 52-Week Low
• Negative Sentiment: Johnson Fistel announced an investor investigation into potential claims against Surgery Partners’ executives, adding legal/settlement risk and likely increasing investor caution. GlobeNewswire: Investor Investigation

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.